Mr. Garner brings over 25 years of pharmaceutical industry experienceTHE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals,…
Booth #2450-22 (DiMe Virtual First Care Pavilion) and Booth #4950-5 (CareQuest Systemic Health Pavilion)METUCHEN, N.J.--(BUSINESS WIRE)--Dentistry.One, a virtual-first dental care…
Direct Access Lab Company is Among Leaders in the Health and Medical SectorATLANTA, GA / ACCESSWIRE / September 28, 2023…
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure SCORED was one of two randomized, double-blind, placebo-controlled Phase…
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology…
The first academic center activated to enroll, led by an instrumental investigator who participated in Femasys’ earlier FemBloc studies -FemBloc…
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral…
--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult…
SIKLOS® (hydroxyurea) is now covered by State Medicaid programs in 19 states Medunik USA (member of Duchesnay Pharmaceutical Group) is…
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) [p= 0.058] and…